#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma
Click to read this study in JAMA Network Open.
Tag: head and neck squamous cell carcinoma (HNSCC)
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
Click to read this study in JAMA Otolaryngology - Head & Neck Surgery.
Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
#VisualAbstract: Induction chemotherapy with erlotinib does not improve survival in stage III-IV head and neck squamous cell carcinoma
Click to read this study in Clinical Cancer Research.
#VisualAbstract: Pembrolizumab-based therapy is more effective with increasing PD-L1 expression in head and neck squamous cell carcinomas
Click to read this study in the Journal of Clinical Oncology.
Elevated neutrophil-lymphocyte ratio associated with poor prognosis for head and neck cancer
1. This single-centred, observational cohort study demonstrated that among patients with head and neck cancer, a high neutrophil-lymphocyte ratio (NLR) ...
#VisualAbstract: Induction chemotherapy with docetaxel, cisplatin, and cetuximab offers similar outcomes with a potentially more favorable treatment schedule than 5-fluorouracil
Click to read this study in the European Journal of Cancer.
#VisualAbstract: Induction chemotherapy does not improve survival for patients receiving chemoradiotherapy for esophageal squamous cell carcinoma
Click to read the study in Nature Communications.
#VisualAbstract: Sentinel lymph node-guided neck dissection is noninferior to elective dissections for patients with early oral cavity squamous cell carcinoma
Click to read the study in the Journal of Clinical Oncology.
#VisualAbstract: Pembrolizumab plus cetuximab shows early clinical efficacy for patients with recurrent or metastatic head and neck squamous cell carcinoma
Click to read the study in The Lancet Oncology.